Building on the encouraging results of treating spinal muscular atrophy by modifying aberrant splicing in the SMN2 gene [101], it may also possible to develop small molecular drug for the hemophilic mutations that cause aberrant splicing. This evidence concerns the gene SMN2 and spinal muscular atrophy.